Santhera Pharmaceuticals

Historical price data

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company committed to addressing the needs of patients with rare neuromuscular diseases, with a primary focus on Duchenne muscular dystrophy (DMD). The company has dedicated over a decade to researching potential treatments for conditions that currently lack therapeutic options. Santhera's mission centers on making effective medicines available to improve patients' quality of life, with a vision to become a leader in the rare disease treatment landscape.

Disease-area focused research and development strategy targeting specific pathological mechanisms in rare neuromuscular disorders, with over a decade of dedicated experience.

28 drugs in pipeline, 9 in Phase 3

Total raised: $55M

Santhera competes with other biopharma companies focused on rare neuromuscular diseases, such as Sarepta Therapeutics and PTC Therapeutics in DMD, as well as large pharma rare disease units. Its differentiation is based on a long-term, dedicated focus on this specific therapeutic area, aiming to develop deep disease understanding and targeted treatments.